Dr. Frank MottMedical Oncologist
Respected medical oncologist Dr. Frank Mott treats patients with malignant pleural mesothelioma at The University of Texas MD Anderson Cancer Center in Houston.
Get to Know Dr. Frank E. Mott
Dr. Frank Mott is a medical oncologist and associate professor in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
He specializes in head, neck and thoracic cancers, including malignant pleural mesothelioma.
Mott is part of the multidisciplinary mesothelioma treatment program at MD Anderson, which has been ranked the No. 1 cancer care hospital in America by U.S. News & World Report.
MD Anderson specializes in diagnosing rare diseases such as mesothelioma at their earliest stages, when treatment is most effective.
Mott has played a major role in the development of targeted therapies used in combination with chemotherapy or radiotherapy, which have been especially effective in certain types of lung cancer and head and neck cancers.
He also helps direct palliative care interventions and end-of-life management with thoracic cancers.
Specialties of Dr. Frank E. Mott
- Clinical trials
- Targeted therapy
- Nasopharynx cancers
- Head and neck cancers
- Lung cancer
- Pleural mesothelioma
- Palliative care
Dr. Frank E. Mott’s Experience and Medical Education
- The University of Texas MD Anderson Cancer Center
- University of Wisconsin (Fellowship and Residency)
- Texas A&M University College of Medicine (M.D.)
- University of Texas College of Pharmacy
Awards and Certifications
- American Board of Medical Oncology
- American Board of Internal Medicine
Publications of Dr. Frank E. Mott
- Pelster, M.S., Mott, F. & Lewin J. (2020, April). Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer. The Laryngoscope.
- Mott, F.E. & Adams, K.C. (2019, January). Advance Care Planning and End-of-Life Issues in Head and Neck Cancer. Journal of Palliative Care.
- Mott, F.E. (2017, May). Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. Oncology and Therapy.
- Mott, F.E., Cable, C.T. & Sharma, N. (2003, November). Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small cell lung cancer. Clinical Lung Cancer.